Lantheus HoldingsNASDAQ: LNTH

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or the Company), a developer of diagnostic and therapeutic radiopharmaceutical products, has entered into strategic agreements with Lantheus Holdings, Inc. (LNTH.NASDAQ), a leading radiopharmaceutical-focused company, and its affiliates (Lantheus). Lantheus has agreed to make an initial equity investment of A$7.5 million (US$4.99 million) and will have an option to invest a further A$7.5 million (US$5 million) within 6 months on the same terms. Additionally, Radiopharm has agreed to transfer two of its early preclinical assets to Lantheus for A$3.0 million (US$2.0 million) pursuant to a separate transfer and development agreement.

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

In the most recent trading session, Lantheus Holdings (LNTH) closed at $79.28, indicating a -0.78% shift from the previous trading day.

The integrated aPROMISE solution to be demonstrated on Siemens Healthineers' syngo.via platform at the SNMMI annual meeting The integrated aPROMISE solution to be demonstrated on Siemens Healthineers' syngo.via platform at the SNMMI annual meeting

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the William Blair 44th Annual Growth Stock Conference at 2:40 p.m. CT on Tuesday, June 4.

Lantheus Holdings (LNTH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

The mean of analysts' price targets for Lantheus Holdings (LNTH) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.